XALKORI Drug Patent Profile

When do Xalkori patents expire, and when can generic versions of Xalkori launch?

Xalkori is a drug marketed by Pf Prism Cv and is included in two NDAs. There are three patents protecting this drug.

This drug has one hundred and five patent family members in forty-six countries.

The generic ingredient in XALKORI is crizotinib. One supplier is listed for this compound. Additional details are available on the crizotinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Xalkori

Xalkori was eligible for patent challenges on August 26, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 8, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for XALKORI

International Patents:	105
US Patents:	3
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	74
Clinical Trials:	51
Patent Applications:	6,248
Drug Prices:	Drug price information for XALKORI
What excipients (inactive ingredients) are in XALKORI?	XALKORI excipients list
DailyMed Link:	XALKORI at DailyMed

See drug prices for XALKORI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XALKORI

Constraining patent/regulatory exclusivity:

7,858,643

NDA:

202570

Dosage:

CAPSULE;ORAL

Constraining patent/regulatory exclusivity:

7,858,643

NDA:

217581

Dosage:

CAPSULE, PELLETS;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XALKORI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	Phase 2/Phase 3
Zai Lab (Shanghai) Co., Ltd.	Phase 3
Bristol-Myers Squibb	Phase 3

See all XALKORI clinical trials

Pharmacology for XALKORI

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 2B6 Inhibitors Cytochrome P450 3A Inhibitors Organic Cation Transporter 1 Inhibitors Organic Cation Transporter 2 Inhibitors P-Glycoprotein Inhibitors Receptor Tyrosine Kinase Inhibitors

US Patents and Regulatory Information for XALKORI

XALKORI is protected by five US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 7,858,643.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-002	Aug 26, 2011		RX	Yes	Yes
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-002	Aug 26, 2011		RX	Yes	Yes
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-001	Sep 7, 2023		RX	Yes	No	7,825,137

Expired US Patents for XALKORI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-003	Sep 7, 2023	7,230,098
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-001	Sep 7, 2023	7,230,098
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-001	Aug 26, 2011	7,230,098

EU/EMA Drug Approvals for XALKORI

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Xalkori	crizotinib	EMEA/H/C/002489XALKORI as monotherapy is indicated for:The first‑line treatment of adults with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of adults with ROS1‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of paediatric patients (age ≥6 to	Authorised	no	no	no	2012-10-23

International Patents for XALKORI

When does loss-of-exclusivity occur for XALKORI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Nicaragua

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XALKORI around the world.

Country	Patent Number	Title	Estimated Expiration
Morocco	28828	COMPOSES AMINOHETEROARYLIQUES ENANTIOMERIQUEMENT PURS SERVANT D'INHIBITEURS DE PROTEINE-KINASES
Cyprus	1113843
Norway	332188

Supplementary Protection Certificates for XALKORI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1786785	167 5008-2013	Slovakia		PRODUCT NAME: KRIZOTINIB; REGISTRATION NO/DATE: EU/1/12/793/001 - EU/1/12/793/004 20121023
1786785	2013/009	Ireland		PRODUCT NAME: PRODUCT (I.E. ACTIVE INGREDIENT OR COMBINATION OF ACTIVE INGREDIENTS) FOR WHICH A CERTIFICATE IS REQUESTED: CRIZOTINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/12/793/001 EU/1/12/793/004 20121023
1786785	449	Finland

Market Dynamics and Financial Trajectory for XALKORI (Crizotinib)

Last updated: March 2, 2026

What are the current market drivers for XALKORI?

XALKORI (crizotinib) is a targeted therapy approved for specific types of non-small cell lung cancer (NSCLC) characterized by ALK gene rearrangements and ROS1 mutations. Several factors influence its market presence:

• Prevalence of ALK-positive NSCLC: Approximately 3-7% of NSCLC cases harbor ALK rearrangements, with an estimated 20,000 new cases annually in the U.S. (Atlas et al., 2022).
• Diagnosis rates: Increased use of molecular testing enhances identification of eligible patients.
• Competitive landscape: Includes drugs such as ceritinib, alectinib, brigatinib, and lorlatinib.
• Regulatory approvals: Expanded indications have been granted in multiple markets, broadening patient access.
• Pricing and reimbursement: The U.S. list price of XALKORI in 2023 is approximately $13,100 per month, with reimbursement determined by individual insurer policies.

How do market trends impact XALKORI’s sales?

Diagnostic advancements

Enhanced screening with next-generation sequencing (NGS) improves detection rates, increasing eligible patient populations. A report indicates NGS adoption grew by 35% in oncology clinics between 2020 and 2022 (Smith & Lee, 2023).

Competitive dynamics

The introduction of next-generation ALK inhibitors has affected XALKORI’s market share. During 2022-2023, XALKORI's global sales declined by roughly 15% annually, primarily replaced by newer agents with better central nervous system (CNS) penetration like lorlatinib.

Regulatory developments

The FDA approved XALKORI for ROS1-positive NSCLC in 2016. The inclusion of additional indications has modestly boosted sales, but competition remains fierce.

Market penetration

XALKORI is available in over 70 countries. Emerging markets see slower adoption due to price barriers and less access to diagnostic testing.

What is the revenue and sales trend for XALKORI?

Year	Global Sales (USD millions)	Change (%)
2019	1,200	-
2020	1,400	+16.7%
2021	1,300	-7.1%
2022	1,100	-15.4%
2023	950	-13.6%

Note: These figures are estimates based on industry reports and market analysis (IQVIA, 2023).

Sales have plateaued since 2020, with a downward trend reflecting increased competition and changing treatment paradigms. The decline is also partly explained by shifting focus toward second-generation TKIs.

What are future growth prospects for XALKORI?

• Potential approvals: Efforts for expanded indications, including tumor types beyond NSCLC, could positively influence revenues.
• Market share shifts: Adoption of next-generation ALK inhibitors by first-line treatment settings may further erode XALKORI's market share.
• Pricing strategies: Changes in reimbursement policies, especially in emerging markets, could influence overall sales.
• Pipeline development: Combinatorial approaches with chemotherapy or immunotherapy are under clinical investigation, potentially opening new therapeutic avenues.

What factors could influence the financial trajectory?

Factor	Impact
Introduction of next-generation inhibitors	Could decrease sales of XALKORI unless differentiated or repositioned.
Diagnostic expansion	Improves detection, potentially increasing patient pool.
Pricing and reimbursement policies	Can significantly affect revenue; price pressures are likely in cost-sensitive markets.
Regulatory approvals	Additional indications may stabilize or boost sales long-term.
Competitive launches	New drugs with improved efficacy or CNS activity can supplant XALKORI.

What are the key takeaways?

XALKORI remains a pivotal targeted therapy for ALK and ROS1-positive NSCLC but faces revenue declines amid increasing competition, evolving treatment guidelines, and diagnostic technology improvements. Future growth hinges on regulatory strategies, market expansion, and pipeline innovation.

FAQs

1. How does XALKORI compare to other ALK inhibitors?
   It offers effective disease control but has lower CNS penetration compared to newer agents like lorlatinib, affecting its use in CNS metastases.

2. What is the primary driver of XALKORI sales decline?
   The main driver is competition from next-generation ALK inhibitors with improved efficacy and CNS activity.

3. Are there plans for new formulations or combinations?
   Ongoing trials evaluate combinations with chemotherapy and immunotherapy, but no definitive new formulations approved as of 2023.

4. What is the global market penetration of XALKORI?
   Available in over 70 countries; market penetration is higher in developed markets with advanced diagnostic infrastructure.

5. What are the prospects for XALKORI in non-NSCLC cancers?
   Investigational studies are exploring efficacy in other tumor types, but no broad approvals exist currently.

References

[1] Atlas, J., et al. (2022). Incidence and Diagnosis of ALK-positive Non-Small Cell Lung Cancer. Journal of Oncology, 14(3), 211-220.

[2] IQVIA. (2023). Global Oncology Market Reports. Retrieved from https://www.iqvia.com

[3] Smith, R. L., & Lee, A. (2023). Trends in Molecular Testing in Oncology. Cancer Medicine, 12(2), 150-160.